Physician profile
Heidi Collins
NPI 1336606078
$2,041.50
in general payments reported to CMS, 2019-2025
23 companies · $657 in 2025
The $657 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $60.40 · 2023: $667 · 2024: $657 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.32 | 2023-2025 | |
| Glaxosmithkline, LLC. | $307.81 | 2022-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $150.44 | 2022-2025 | Jardiance, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $126.93 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.23 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $80.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $73.45 | 2023-2025 | Rexulti |
| Amgen INC. | $71.95 | 2023-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $64.47 | 2023-2024 | Rybelsus, Ozempic |
| Hologic Sales and Service, LLC | $60.78 | 2024 | Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $43.42 | 2023-2025 | |
| Dexcom, INC. | $37.30 | 2023-2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $25.14 | 2024 | Auvelity |
| Biogen, INC. | $24.05 | 2025 | Skyclarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.69 | 2023 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $23.26 | 2024 | Sublocade |
| Novartis Pharmaceuticals Corporation | $22.87 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.13 | 2025 | Trintellix |
| Tactile Systems Technology INC | $20.26 | 2023 | Entre Plus, Flexitouch Plus |
| Merck Sharp & Dohme LLC | $19.99 | 2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.99 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $17.47 | 2024 | |
| Medtronic, INC. | $14.94 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.